Oxidative phosphorylation defects and Alzheimer's disease

Neurogenetics. 1997 May;1(1):13-9. doi: 10.1007/s100480050002.

Abstract

Abnormalities in cellular bioenergetics have been identified in patients with Alzheimer's disease (AD) as well as in patients with other neurodegenerative diseases. The most commonly reported enzyme abnormalities are in the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, and oxidative phosphorylation (OXPHOS). Although genetic evidence supporting primary OXPHOS defects as a cause for AD is weak, functionally important reductions in OXPHOS enzyme activities appear to occur in AD and may be related to beta-amyloid accumulation or other neurodegenerative processes. Since reduced neuronal ATP may enhance susceptibility to glutamate toxicity, OXPHOS defects could play an important role in the pathophysiology of AD.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Alzheimer Disease / enzymology*
  • Alzheimer Disease / genetics*
  • Amyloid beta-Peptides / genetics
  • DNA, Mitochondrial
  • Electron Transport Complex IV / genetics
  • Glutamic Acid / genetics
  • Humans
  • Models, Biological
  • Mutation
  • Oxidative Phosphorylation*

Substances

  • Amyloid beta-Peptides
  • DNA, Mitochondrial
  • Glutamic Acid
  • Electron Transport Complex IV